Die kostenlosen ARIVA.DE Börsen-Dienste:
Bleiben Sie immer informiert und melden Sie sich jetzt für die Newsletter von ARIVA.DE an!
Jetzt kostenlos abonnieren

Investor 2020: Vassago

Cashbestand:
16.377,79 €
Platz:
Gesamtwert mit Cash:
128.722,58 € (15.01.21 06:31)
Börsenspiel beendet. Diese Werte werden nicht mehr aktualisiert.
Kurse zum Spielende    

News

Zeit
Titel
Wertpapier
 
Do Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
Nektar Therapeutics
22.03.24 Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics
05.03.24 Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
Nektar Therapeutics
04.03.24 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Nektar Therapeutics
04.03.24 Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
Nektar Therapeutics
27.02.24 Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
Nektar Therapeutics
26.02.24 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
Nektar Therapeutics
03.01.24 Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Nektar Therapeutics
11.12.23 Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
Nektar Therapeutics
07.11.23 Nektar Therapeutics Reports Third Quarter 2023 Financial Results
Nektar Therapeutics
31.10.23 Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
Nektar Therapeutics
13.10.23 Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
Nektar Therapeutics
02.10.23 Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Nektar Therapeutics
29.09.23 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
Myovant Sciences
27.09.23 Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
Nektar Therapeutics
13.09.23 Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
06.09.23 Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
Nektar Therapeutics
08.08.23 Nektar Therapeutics Reports Second Quarter 2023 Financial Results
Nektar Therapeutics
07.08.23 Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
Nektar Therapeutics
01.08.23 Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
Nektar Therapeutics
12.06.23 Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
Nektar Therapeutics
27.04.23 Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
Nektar Therapeutics
17.04.23 Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
Nektar Therapeutics
29.03.23 Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600
Nektar Therapeutics
11.03.23 Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
Nektar Therapeutics
28.02.23 Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
Nektar Therapeutics
23.02.23 Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
Nektar Therapeutics
26.01.23 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV
Myovant Sciences
12.01.23 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, IMRA, MYOV, IAA
Myovant Sciences
11.01.23 MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
Myovant Sciences
Do
Nektar Therapeutics
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
22.03.24
Nektar Therapeutics
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
05.03.24
Nektar Therapeutics
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
04.03.24
Nektar Therapeutics
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
04.03.24
Nektar Therapeutics
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
27.02.24
Nektar Therapeutics
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
26.02.24
Nektar Therapeutics
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
03.01.24
Nektar Therapeutics
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
11.12.23
Nektar Therapeutics
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
07.11.23
Nektar Therapeutics
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
31.10.23
Nektar Therapeutics
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
13.10.23
Nektar Therapeutics
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
02.10.23
Nektar Therapeutics
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
29.09.23
Myovant Sciences
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
27.09.23
Nektar Therapeutics
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
13.09.23
Nektar Therapeutics
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
06.09.23
Nektar Therapeutics
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
08.08.23
Nektar Therapeutics
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
07.08.23
Nektar Therapeutics
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
01.08.23
Nektar Therapeutics
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
12.06.23
Nektar Therapeutics
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
27.04.23
Nektar Therapeutics
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
17.04.23
Nektar Therapeutics
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
29.03.23
Nektar Therapeutics
Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600
11.03.23
Nektar Therapeutics
Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
28.02.23
Nektar Therapeutics
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
23.02.23
Nektar Therapeutics
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
26.01.23
Myovant Sciences
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV
12.01.23
Myovant Sciences
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, IMRA, MYOV, IAA
11.01.23
Myovant Sciences
MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
Musterdepot - © Ismagilov / Shutterstock

Das kostenlose Musterdepot von ARIVA.DE

Bei einem niedrigen Kurs einsteigen, bei einem hohen Kurs wieder verkaufen – es klingt einfach, an der Börse Erfolg zu haben. Tatsächlich brauchen Aktionäre gute Nerven, wenn die Kurse auf und ab schwanken. Realistische Anlageziele, eine klare Linie bei der Auswahl der Wertpapiere und das clevere Einsetzen bestimmter Ordertypen gehören zum Handwerk beim Handel mit Wertpapieren.

Um ein Gefühl dafür zu bekommen, welche Strategien in welchen Börsenphasen fruchten, können Nutzerinnen und Nutzer bei ARIVA.DE kostenlos ein Musterdepot anlegen und Wertpapiere wie Anleihen, Aktien, Derivate oder Fonds virtuell im Musterdepot handeln. Die Orders werden zum Schein ausgeführt und finden sich dann in einem virtuellen Musterdepot, ohne dass die Papiere tatsächlich ge- oder verkauft werden. So lassen sich Anlagestrategien testen, ohne Geld zu riskieren.

Viele Nutzer bauen auf ARIVA.DE im Musterdepot ihr reales Depot nach, das ein Broker für sie führt. Grund: Beim Musterdepot auf ARIVA.DE ist jede Position mit den zugehörigen News, dem Forum und der Profilseite verlinkt. Über die Aktien auf dem Laufenden zu bleiben, ist durch das Musterdepot sehr einfach. Möglich ist es auf ARIVA.DE auch, interessante Wertpapiere in eine Watchlist aufzunehmen, um ihre Entwicklung im Auge zu behalten. Nutzer können dabei Kursgrenzen vorgeben und sich bei Erreichen benachrichtigen lassen.

Übrigens: Wer ein virtuelles Musterdepot im Rahmen eines der Börsenspiele von ARIVA.DE eröffnet, hat einen weiteren Lerneffekt: Beim Börsenspiel wird ein Budget vorgegeben, und für jede Transaktion fallen virtuelle Gebühren an. Das macht den „Scheinhandel“ noch realistischer.